Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70750 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Sihui Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Bureau Fund of Sichuan Province of China, Beijing E town Coorperation & Development Foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION We investigated real‐world efficacy, safety, and plasma biomarker dynamics of Lecanemab in Chinese patients with Alzheimer's disease (AD). METHODS A multi‐center prospective cohort study enrolled 68 AD patients. Cognitive scales and plasma biomarkers were assessed at baseline (V0), 2.5 months (V1), and 7 months (V2). RESULTS Alzheimer's Disease Assessment Scale‐Cognitive Subscale 14‐item version (ADAS‐cog14) scores improved significantly at both follow‐ups, and plasma p‐tau181 consistently declined. Both p‐tau181 and p‐tau217 correlated with cognition and partially predicted treatment response (area under the curve [AUC] = 0.734 and 0.713). Mixed‐effects modeling confirmed their dynamic association with ADAS‐cog14 scores. Subgroup analyses indicated benefits across sex and apolipoprotein E4 status, while moderate‐to‐severe cases showed limited response. Lecanemab was well tolerated, with asymptomatic amyloid‐related imaging abnormalities in 17.65% and mild infusion reactions in 5.88%. DISCUSSION These findings support the short‐term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment‐responsive biomarker. Highlights Lecanemab improved cognitive function in Chinese patients with mild cognitive impairment due to Alzheimer's disease (AD‐MCI) and mild AD over a short period. Plasma p‐tau181 and p‐tau217 showed significant correlation with cognitive scores, and their baseline level could partially predict the efficacy of lecanemab. Lecanemab showed a favorable safety profile with low, manageable rates of amyloid‐related imaging abnormalities (ARIA) and infusion reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Neurology, Central Hospital of Panzhihua, Middle Section of Panzhihua Avenue, Dong District, Panzhihua, Sichuan, China.
- Department of Neurology, Suining First People's Hospital, Suining, Sichuan, China.
- Department of Neurology, The Affiliated Hospital of Sichuan Nursing Vocational College, Sichuan Provincial Third People's Hospital, Chengdu, Sichuan, China.
- Department of Neurology, Sichuan Provincial Fifth People's Hospital, Chengdu, Sichuan, China.
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
ORCID-Profile: Xueping Chen
Förderung
- National Natural Science Foundation of China
- Science and Technology Bureau Fund of Sichuan Province of China
- Beijing E town Coorperation & Development Foundation
- the Sichuan Provincial Cadre Healthcare Research Project
- the Sci-Tech Innovation 2023 "Brain Science and Brain-like Research
Zitieren
APA
Chen, S., Ou, R., Wei, Q., Li, C., Song, W., Zhao, B., Yang, J., Fu, J., Ma, Y., Liu, J., Wang, X., Fang, D., Hu, T., Xiao, L., Zhang, S., Huang, R., Guo, X., Feng, F., Chen, X., & Shang, H. (2025). Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70750
Vancouver
Chen S, Ou R, Wei Q, Li C, Song W, Zhao B, et al. Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70750
BibTeX
@article{Chen2025,
author = {Chen, Sihui and Ou, Ruwei and Wei, Qianqian and Li, Chunyu and Song, Wei and Zhao, Bi and Yang, Jing and Fu, Jiajia and Ma, Yuanzheng and Liu, Jiyong and Wang, Xiangming and Fang, Dengfu and Hu, Tao and Xiao, Li and Zhang, Shushan and Huang, Rui and Guo, Xiaoyan and Feng, Fei and Chen, Xueping and Shang, Huifang},
title = {Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70750}
}
EUVIMED